PILA PHARMA ANNOUNCES INITIATION OF STUDY IN PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Researc...
PILA PHARMA INVITES TO NORDIC INVESTOR MEETINGS
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") (FN STO: PILA) hereby invites you to participate in these upcoming Nordic investor events:
PILA PHARMA AB Chairman & CEO increase their holdings
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company"), (FN STO: PILA), today announces that Chairman of the Board, Dorte X. Gram and CEO Gustav H. Gram have purchased additional...
PILA PHARMA TO PARTICIPATE IN DANISH INVESTMENT PODCAST "MILLIONÆRKLUBBEN"
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites you to view and/or listen to the broadcast from todays episode of "Millionærklubben" (Millionaire's Club) where PILA PHARMA's...
REG
MAR
PILA PHARMA ANNOUNCES SELECTION OF CLINICAL TRIAL SITE AND DECISION TO SEEK SCIENTIFIC ADVICE FOR OPTIMIZED PP-CT03 STUDY DESIGN
PILA PHARMA AB (publ) (FN STO:PILA) today announces the selection of the principal investigator, Professor Mark Evans and Cambridge University Hospital as principal clinical tria...
REG
MAR
PILA PHARMA ANNOUNCES PROGRESSION AND CO-SPONSORSHIP OF PRECLINICAL RESEARCH COLLABORATION IN CARDIOVASCULAR DISEASE
PILA PHARMA AB (publ) ("PILA PHARMA" or the "Company") today announces the co-sponsorship of the research collaboration with the Research Group of Professor Dick Wågsäter, Uppsal...
REG
MAR
PILA PHARMA INFORMS OF OPTIMIZATION CHANGES TO TRIAL PLAN
PILA PHARMA AB (publ) (FN STO:PILA) today announces it has chosen to alter the operational plan for its next clinical trial, PP-CT03, a phase 2a safety and tolerability trial in...
CEO Gustav H. Gram increases holding in PILA PHARMA AB
Pila Pharma AB (publ) (FN STO: PILA) announces that recently appointed CEO Gustav H. Gram has purchased additional shares. The purchases occurred on Wednesday, 30 August, where 2...
REG
MAR
PILA PHARMA publishes interim report (1 January - 30 June 2024)
PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period January - June 2024. The report can be found on the Company´s website: https://pi...
PILA PHARMA INVITES TO INVESTOR Q&A & PRESENTATIONS
PILA PHARMA AB (publ) (FN STO: PILA) hereby invites interested investors to participate in our scheduled events in the coming week:___________Stokk.io Online Webinar - H2 Report...
REG
MAR
PILA PHARMA'S BOARD OF DIRECTORS ANNOUNCES COMPLETION OF A FULLY SUBSCRIBED DIRECTED ISSUE OF APPROXIMATELY SEK 10 MILLION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAN...
REG
MAR
PILA PHARMA INKS AGREEMENT WITH LINDUS HEALTH ABOUT NEXT CLINICAL TRIAL WITH SAFETY AND OBESITY READOUTS
PILA PHARMA AB (publ) (FN STO:PILA) today announces it has entered into agreement with a United Kingdom based clinical research organisation, Lindus Health, on supply of clinica...
REG
MAR
PILA PHARMA'S BOARD OF DIRECTORS HAS RESOLVED TO CARRY OUT A DIRECTED ISSUE OF SHARES OF APPROXIMATELY SEK 10.0 MILLION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAN...
Clarification: PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE
Dispatch missing first section with scientific meeting information.
PILA PHARMA today announces it's participation in and co-sponsorship of the 41st International Symposium on D...
PILA PHARMA SPONSORS INTERNATIONAL DIABETES & NUTRITION CONFERENCE
PILA PHARMA today announces it's participation in and co-sponsorship of the 41st International Symposium on Diabetes and Nutrition, organized by the Diabetes and Nutrition Study...
PILA PHARMA PRESENTS TOMORROW AT "AKTIESPARARNA"
PILA PHARMA AB (publ) (FN STO: PILA) announces that it will present tomorrow at the Aktiespararna's "Store Aktiedagarna" event.
PILA PHARMA PRESENTS TODAY AT REDEYE THEME: DIABETES
PILA PHARMA AB (publ) (FN STO: PILA) announces that it will present today at the Redeye Theme: Diabetes.
CEO Gustav H. Gram increases holding in Pila Pharma AB
Pila Pharma AB (publ) (FN STO: PILA) announces that newly appointed CEO Gustav H. Gram has purchased additional shares. The purchases occurred in two tranches: Friday May 10th, w...
Om PILA PHARMA
Webbplats
pilapharma.com
Prenumerera
Få löpande information från PILA PHARMA via e-post.
Handelsinformation
Kurs ()
Förändring ()